These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35286367)

  • 1. US Food and Drug Administration-Mandated Postmarketing Studies for High-risk Cardiovascular Devices Approved 2015-2019.
    Hidano D; Dhruva SS; Redberg RF
    JAMA Intern Med; 2022 May; 182(5):556-558. PubMed ID: 35286367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
    Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
    Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-risk Therapeutic Devices Approved by the US Food and Drug Administration for Use in Children and Adolescents From 2016 to 2021.
    Pathak K; Narang C; Hwang TJ; Espinoza JC; Bourgeois FT
    JAMA Pediatr; 2023 Jan; 177(1):98-100. PubMed ID: 36342722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020.
    Moneer O; Lee CC; Avorn J; Kesselheim AS
    JAMA Netw Open; 2021 Apr; 4(4):e218530. PubMed ID: 33929526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmarketing trials and pediatric device approvals.
    Hwang TJ; Kesselheim AS; Bourgeois FT
    Pediatrics; 2014 May; 133(5):e1197-202. PubMed ID: 24733871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Safety Communications After US Food and Drug Administration Approval of Contemporary Cancer Therapies.
    Bonsu JM; Kola-Kehinde O; Kim L; Ruz P; Campbell CM; Brammer JE; Addison D
    JAMA Oncol; 2021 Nov; 7(11):1722-1723. PubMed ID: 34591072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.
    Fan M; Chan AYL; Yan VKC; Tong X; Lau LKW; Wan EYF; Tam EYT; Ip P; Lum TY; Wong ICK; Li X
    Orphanet J Rare Dis; 2022 Jan; 17(1):3. PubMed ID: 34983612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):243-246. PubMed ID: 29871507
    [No Abstract]   [Full Text] [Related]  

  • 12. Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration.
    Egilman A; Wallach JD; Puthumana J; Zhang AD; Schwartz JL; Ross JS
    J Gen Intern Med; 2021 Oct; 36(10):3281-3284. PubMed ID: 34131876
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug approval system questioned in US and Canada.
    Eggertson L
    CMAJ; 2005 Feb; 172(3):317-8. PubMed ID: 15684107
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA fails to monitor fast tracked drugs after approval, says US watchdog.
    Dyer O
    BMJ; 2016 Jan; 532():i371. PubMed ID: 26791241
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 16. Preapproval Promises to Voluntarily Withdraw FDA-Approved Drugs.
    Fernandez Lynch H; Sachs RE
    JAMA; 2022 Dec; 328(24):2392-2393. PubMed ID: 36480185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015.
    MacGregor A; Zhang AD; Wallach JD; Ross JS; Herder M
    JAMA Netw Open; 2020 Jul; 3(7):e209498. PubMed ID: 32706379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Sponsor's View on Postmarketing Regulatory Commitments Involving Human Drug Products.
    McKinley L; Pressler ML; Hiatt MA; Gregory W
    Clin Pharmacol Ther; 2022 Jun; 111(6):1199-1201. PubMed ID: 34251029
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018.
    Wallach JD; Ramachandran R; Bruckner T; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133601. PubMed ID: 34751764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US Senate passes FDA Revitalization Act.
    Guthrie P
    CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.